NORFLOXACIN

Search structure
Trade Names:
Synonyms:
Status: Approved (1986)
Entry Type: Small molecule
Molecule Category: Parent
ATC: J01MA06
UNII: N0F8P22L1P

Structure
InChI Key OGJPXUAPXNRGGI-UHFFFAOYSA-N
Smile CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21
InChI
InChI=1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23)

Physicochemical Descriptors

Property Name Value
Molecular Formula C16H18FN3O3
Molecular Weight 319.34
AlogP 1.27
Hydrogen Bond Acceptor 5.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 3.0
Polar Surface Area 74.57
Molecular species ZWITTERION
Aromatic Rings 2.0
Heavy Atoms 23.0

Experimental and Estimated Properties

Property Name Value Unit Method
log P (octanol-water) -1.03E+00 - EXP
Henry's Law Constant 8.70E-19 atm-m3/mole EST
Atmospheric OH Rate Constant 3.22E-10 cm3/molecule-sec EST
Melting Point 227-228 deg C EXP
Water Solubility 1.78E+05 mg/L EST
Vapor Pressure 6.77E-13 mm Hg EST

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Bacterial DNA gyrase inhibitor FDA
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Isomerase
- 600-18600 - - -
Enzyme
- 600-18600 - - -
Ion channel Ligand-gated ion channel GABA-A receptor
- 20-13000 - - -
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- - - - 100
Transporter Primary active transporter ATP-binding cassette ABCB subfamily
- - 98400 - -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Liver Cirrhosis 3 D008103 ClinicalTrials
Peritonitis 3 D010538 ClinicalTrials
Esophageal and Gastric Varices 3 D004932 ClinicalTrials
Urinary Tract Infections 3 D014552 ClinicalTrials
Hepatopulmonary Syndrome 2 D020065 ClinicalTrials
Osteomyelitis 0 D010019 ClinicalTrials

Related Entries

MCS

Scaffolds

Side Effects from Label

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Musculoskeletal and connective tissue disorders
15.82
Nervous system disorders
10.77
General disorders and administration site conditions
9.76
Skin and subcutaneous tissue disorders
9.43
Injury, poisoning and procedural complications
6.4
Immune system disorders
6.06
Blood and lymphatic system disorders
4.71
Hepatobiliary disorders
4.71
Gastrointestinal disorders
3.7
Vascular disorders
3.03
Ear and labyrinth disorders
2.69
Infections and infestations
2.69
Renal and urinary disorders
2.69
Surgical and medical procedures
2.69
Investigations
2.36
Respiratory, thoracic and mediastinal disorders
2.36
Cardiac disorders
2.02
Psychiatric disorders
2.02

Cross References

Resources Reference
CAS NUMBER 70458-96-7
ChEBI 100246
ChEMBL CHEMBL9
DrugBank DB01059
DrugCentral 1967
EPA CompTox DTXSID7037680
FDA SRS N0F8P22L1P
Human Metabolome Database HMDB0015192
KEGG C06687
PharmGKB PA450654
PubChem 4539
SureChEMBL SCHEMBL3473
ZINC ZINC000000003742
CONTENTS